NMR screening for lead compounds using tryptophan-mutated proteins.

Article Details

Citation

Copy to clipboard

Rothweiler U, Czarna A, Weber L, Popowicz GM, Brongel K, Kowalska K, Orth M, Stemmann O, Holak TA

NMR screening for lead compounds using tryptophan-mutated proteins.

J Med Chem. 2008 Aug 28;51(16):5035-42. doi: 10.1021/jm8002813. Epub 2008 Aug 5.

PubMed ID

18680271 [ View in PubMed

]

Abstract

NMR-based drug screening methods provide the most reliable characterization of binding propensities of ligands to their target proteins. They are, however, one of the least effective methods in terms of the amount of protein required and the time needed for acquiring an NMR experiment. We show here that the introduction of tryptophan to proteins permits rapid screening by monitoring a simple 1D proton NMR signal of the NH side chain ((N)H(epsilon)) of the tryptophan. The method could also provide quantitative characterization of the antagonist-protein and antagonist-protein-protein interactions in the form of KDs and fractions of the released proteins from their mutual binding. We illustrate the method with the lead compounds that block the Mdm2-p53 interaction and by studying inhibitors that bind to cyclin-dependent kinase 2 (CDK2).

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Seliciclib	Cyclin-dependent kinase 2	IC 50 (nM)	100	N/A	N/A	Details